PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Prithviraj Bose, MD / Jeanne M. Palmer, MD - State-of-the-Art Solutions for Myelofibrosis: The Intersection of JAK Inhibitors, Allogeneic Transplant, and Other Strategies for Patient Care
Go online to PeerView.com/UQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in the management of myelofibrosis (MF) offers learners an update on the modern diagnostic and risk assessment strategies that have informed a more considered treatment approach to symptomatic disease. An emerging paradigm, in which potentially curative hematopoietic cell transplantation (HCT) is used in conjunction with Janus kinase (JAK) inhibitor therapy, is discussed, along with an expert-led assessment of JAK inhibitor options in development for MF and how these additions to the treatment arsenal will be used alongside standard approaches. For professionals who are looking to pair recent evidence on JAK inhibitors with HCT and other options in the management of MF, this educational event is an essential disease management resource. Upon completion of this activity, participants should be better able to: Identify clinical symptoms and molecular/mutational features that can be used to diagnose and risk-stratify myelofibrosis, Discuss the current treatment role of JAK inhibitors and allogeneic transplantation in the management of myelofibrosis, Cite recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of myelofibrosis, Develop risk-adapted treatment plans for patients with symptomatic myelofibrosis, including those who did not respond to previous JAK inhibitor therapy or are eligible for allogeneic transplantation.